SRR662570
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.432
- MYC_TARGETS_V1+0.309
- OXIDATIVE_PHOSPHORYLATION+0.252
- MYC_TARGETS_V2+0.191
- PI3K_AKT_MTOR_SIGNALING+0.183
- DNA_REPAIR+0.177
- UNFOLDED_PROTEIN_RESPONSE+0.177
- E2F_TARGETS+0.162
- G2M_CHECKPOINT+0.097
- ANDROGEN_RESPONSE+0.085
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.567
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.499
- INTERFERON_GAMMA_RESPONSE-0.489
- TNFA_SIGNALING_VIA_NFKB-0.476
- COAGULATION-0.466
- ANGIOGENESIS-0.457
- INFLAMMATORY_RESPONSE-0.443
- APOPTOSIS-0.419
- IL6_JAK_STAT3_SIGNALING-0.411
- WNT_BETA_CATENIN_SIGNALING-0.396
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR656179 | GTEX | — | 0.976 |
| 2 | SRR2167642 | GTEX | — | 0.974 |
| 3 | SRR660812 | GTEX | — | 0.973 |
| 4 | SRR819999 | GTEX | — | 0.968 |
| 5 | SRR664819 | GTEX | — | 0.964 |
| 6 | SRR659331 | GTEX | — | 0.964 |
| 7 | SRR818188 | GTEX | — | 0.954 |
| 8 | SRR1366057 | GTEX | — | 0.952 |
| 9 | SRR1407560 | GTEX | — | 0.949 |
| 10 | SRR1467364 | GTEX | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.432 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.309 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.252 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.191 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.183 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.177 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.177 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.162 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.097 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.085 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.078 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.071 | Temsirolimus | — uncovered |
| PEROXISOME | 0.061 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.044 | Inavolisib | — uncovered |